Skip to main content
. 2021 Apr;191(4):720–729. doi: 10.1016/j.ajpath.2021.01.003

Figure 6.

Figure 6

Treatment with recombinant pigment epithelium–derived factor (rPEDF) reduces dry eye disease (DED) severity. Efficacy of systemic rPEDF treatment initiated after DED induction for 7 days was assessed. A: Clinical severity of DED on treatment with murine serum albumin (MSA; control) or rPEDF was evaluated using corneal fluorescein staining on days 7, 9, 12, and 14. B: Representative corneal fluorescein staining images captured on days 7, 9, 12, and 14. Data are presented as a representative experiment of the four performed, each consisting of four mice per group. Data are presented as means ± SEM (A). ∗P < 0.05, ∗∗P < 0.01.